期刊
CURRENT RADIOPHARMACEUTICALS
卷 11, 期 3, 页码 200-208出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1874471011666180502104524
关键词
Targeted alpha therapy; alpha emitter; actinium-225; bismuth-213; nuclide production; clinical application
Background: Recent reports of the remarkable therapeutic efficacy of Ac-225-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. Objective and Conclusion: This review describes methods for the production of Ac-225 and its daughter nuclide Bi-213 and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据